Explore

President Trump Fast-Tracks Research and Access to Psychedelic Drugs for Mental Health

President Trump Fast-Tracks Research and Access to Psychedelic Drugs for Mental Health

President Trump has signed an executive order to accelerate research into and access to psychedelic drugs, including ibogaine compounds, as potential treatments for mental health conditions. This initiative includes a $50 million investment for state governments to study how psychedelics might aid individuals struggling with mental illnesses. The executive order also directs the FDA to provide national priority vouchers for certain psychedelic drugs, aiming to speed up the review process for approval. This move follows advocacy from high-profile supporters like podcast host Joe Rogan, who stated he provided information to President Trump that led to the swift decision. Ibogaine, a psychoactive compound from an African shrub, has shown early promise in altering neural pathways, potentially improving conditions such as PTSD, anxiety, and depression. Despite being classified as a Schedule I substance by the DEA, meaning it has no accepted medical use and a high potential for abuse, the FDA has a system to de-...

Experimental Drug Kamuvudine K-9 Shows Promise in Reversing Multiple Sclerosis Damage in Mouse Model

Experimental Drug Kamuvudine K-9 Shows Promise in Reversing Multiple Sclerosis Damage in Mouse Model

A new experimental drug, Kamuvudine K-9, developed by a UVA Health scientist, has demonstrated the ability to not only halt but also reverse paralysis and vision loss in a mouse model of multiple sclerosis (MS). Unlike existing MS treatments that primarily aim to reduce future inflammatory attacks, K-9 has shown the capacity to restore neurological function that was already lost. The drug, a derivative of approved HIV medications known as nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), preserved nerve fibers and their myelin insulation, which are typically destroyed by MS. It also prevented the increase of neurofilament light chain (NfL), a blood biomarker indicating nerve damage. Analysis of health insurance data from over 3 million people further supports the potential of NRTI-derived drugs, showing a 41% reduction in MS development risk and a 36% reduction in annual relapse rates among MS patients using NRTIs. K-9 is currently undergoing clinical trials for eye diseases, including diabet...

Compassion Behavioral Health Publishes Resource on GLP-1 Research for Alcohol Use Disorder

Compassion Behavioral Health Publishes Resource on GLP-1 Research for Alcohol Use Disorder

Compassion Behavioral Health, a treatment provider based in Fort Lauderdale, Florida, has published a new educational resource examining emerging research on GLP-1 receptor agonist medications, such as semaglutide, and their potential relationship to alcohol cravings and alcohol use disorder (AUD). The resource reviews current scientific understanding, placing early findings within the broader context of addiction treatment. It emphasizes that while GLP-1 medications, primarily developed for type 2 diabetes and weight management, show promise in influencing neural pathways related to reward-seeking behaviors, no GLP-1 receptor agonist is currently approved by the U.S. Food and Drug Administration (FDA) specifically for AUD. The article highlights that reducing cravings alone does not address all psychological, behavioral, medical, or environmental factors contributing to problematic alcohol use.

What to know about ibogaine, the drug Presley Gerber used for treatment months before death

What to know about ibogaine, the drug Presley Gerber used for treatment months before death

Presley Gerber shared his experience with ibogaine months before his death. What is the psychedelic compound? Why is it used in addiction treatment?

Incyte to Present Extensive Data on Inflammation and Autoimmunity Portfolio at EADV Congress

Incyte to Present Extensive Data on Inflammation and Autoimmunity Portfolio at EADV Congress

Incyte (Nasdaq: INCY) announced it will present a broad range of data from its Inflammation and Autoimmunity (IAI) portfolio at the European Academy of Dermatology and Venereology (EADV) 2026 Congress, scheduled from September 30 to October 3, 2026, in Vienna, Austria. The presentations will cover various immune-mediated skin diseases, including atopic dermatitis, hidradenitis suppurativa, prurigo nodularis, and vitiligo. Key data will include oral presentations on atopic dermatitis and its impact on quality of life, as well as numerous poster presentations detailing comparative efficacy, long-term safety, and patient-reported outcomes for treatments like ruxolitinib cream (Opzelura®) and povorcitinib. The data aims to deepen the understanding of patient experiences and advance innovation in these therapeutic areas.

Wearables in Clinical Trials Face Integration and Standardization Challenges

Wearables in Clinical Trials Face Integration and Standardization Challenges

Wearable devices are increasingly being incorporated into clinical trials, often as part of broader digital product strategies rather than being fully integrated into the core clinical development strategy. This approach can lead to several issues, including the treatment of wearable data collection as optional, a lack of operational rigor, and insufficient attention to adherence compared to established clinical endpoints. Digital health teams, which often operate separately from clinical development teams, may struggle to demonstrate the clinical relevance of their solutions. This disconnect means that while wearables offer significant opportunities to extend the impact of therapeutic interventions, their full potential in generating robust longitudinal evidence for clinical decision-making is not being realized. The current dynamic often results in wearable-derived measurements being relegated to exploratory or supportive roles, rather than becoming primary or key secondary endpoints.

Microbiome Therapeutics Market Poised for Significant Growth Driven by Personalized Medicine and AI Integration

Microbiome Therapeutics Market Poised for Significant Growth Driven by Personalized Medicine and AI Integration

Microbiome Therapeutics Market Poised for Significant Growth Driven by Personalized Medicine and AI Integration

UC San Diego Researchers Identify Natural Peptide to Combat Alzheimer's Disease

UC San Diego Researchers Identify Natural Peptide to Combat Alzheimer's Disease

Researchers at the University of California San Diego School of Medicine and the VA San Diego Healthcare System have identified a naturally occurring peptide fragment called catestatin (CST) that shows promise in treating neurodegenerative diseases like Alzheimer's. Published in Molecular Therapy, their study in animal models demonstrated that CST can simultaneously reduce the accumulation of amyloid and tau proteins, decrease neuroinflammation, and improve cognitive and motor functions. Unlike many experimental drugs that target single aspects of these diseases, CST intervenes across multiple interconnected pathological pathways. The peptide is derived from chromogranin A, a protein involved in neurotransmitter storage and cellular signaling, suggesting its broad systemic versatility extends to the central nervous system. This multi-target approach addresses the complex nature of neurodegenerative disorders, which involve a network of problems including protein aggregation, inflammation, metabolic dysfunc...

Artificial Intelligence Transforms Gene Therapy Development, Addressing Key Challenges in U.S. Healthcare

Artificial Intelligence Transforms Gene Therapy Development, Addressing Key Challenges in U.S. Healthcare

Artificial Intelligence (AI) is revolutionizing the field of gene therapy, impacting every stage from target discovery to clinical translation. AI technologies, including machine learning, deep learning, and generative AI, are being applied to analyze vast amounts of biological data generated by high-throughput sequencing and multi-omics platforms. This allows for more efficient identification of disease-causing genes, optimization of genome-editing strategies like CRISPR-Cas systems, and the design of novel viral capsids and synthetic delivery systems. For instance, AI-guided directed evolution is significantly reducing the experimental search space for vectors with improved tissue-specificity and immune evasion capabilities. In manufacturing, AI models are being developed to monitor and control bioprocess parameters, aiming to improve the yield and consistency of complex biological products such as viral vectors. The U.S. Food and Drug Administration (FDA) is actively adapting its regulatory frameworks t...

Imago Relationships Therapy Emphasizes Healthy Boundaries for Connection and Self-Care

Imago Relationships Therapy Emphasizes Healthy Boundaries for Connection and Self-Care

Imago Relationships Therapy Emphasizes Healthy Boundaries for Connection and Self-Care

Abbisko Therapeutics Reports Positive Phase 2 Results for Lavengratinib in Achondroplasia Treatment

Abbisko Therapeutics Reports Positive Phase 2 Results for Lavengratinib in Achondroplasia Treatment

Abbisko Therapeutics has announced positive preliminary efficacy results from its Phase II clinical study of lavengratinib (ABSK061), a selective orally available small-molecule FGFR2/3 inhibitor, for children with achondroplasia (ACH). In the initial and lowest dose cohort (0.064mg/kg QD), children aged 6 years and older with ACH who received lavengratinib for 27 weeks showed a mean increase of +2.4 cm/year in annualized height velocity (AHV) from baseline, achieving a 100% responder rate. The drug was well-tolerated, with no observed FGFR1 or FGFR2-associated adverse events. The ABSK061-202 study is a Phase II, multicenter, open-label, dose-escalation study evaluating the safety and efficacy of lavengratinib in children aged 3 to 12 years with ACH, with a planned treatment duration of 78 weeks. Preliminary safety evaluations for the first three dose cohorts have been successfully completed without identifying any safety concerns.

Journaling Offers Therapeutic Benefits for Emotional Healing and Self-Awareness

Journaling Offers Therapeutic Benefits for Emotional Healing and Self-Awareness

Journaling Offers Therapeutic Benefits for Emotional Healing and Self-Awareness